journal article·2023-03-23Open access

Critical Non-Covalent Binding Intermediate for an Allosteric Covalent Inhibitor of SUMO E1

Shristi Pawnikar, Apurba Bhattarai, S. Xiaohu Ouyang, Ramir Vega, Yuan Chen, Yinglong Miao

Abstract

Post-translational modifications by small ubiquitin-like modifiers (SUMOs) are dysregulated in many types of cancers. The SUMO E1 enzyme has recently been suggested as a new immuno-oncology target. COH000 was recently identified as a highly specific allosteric covalent inhibitor of SUMO E1. However, a marked discrepancy was found between the X-ray structure of the covalent COH000-bound SUMO E1 complex and the available structure-activity relationship (SAR) data of inhibitor analogues due to unresolved noncovalent protein-ligand interactions. Here, we have investigated noncovalent interactions between COH000 and SUMO E1 during inhibitor dissociation through novel Ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations. Our simulations have identified a critical low-energy non-covalent binding intermediate conformation of COH000 that agreed excellently with published and new SAR data of the COH000 analogues, which were otherwise inconsistent with the X-ray structure. Altogether, our biochemical experiments and LiGaMD simulations have uncovered a critical non-covalent binding intermediate during allosteric inhibition of the SUMO E1 complex.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ubiquitin and proteasome pathways · Protein Degradation and Inhibitors · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047, United States

SUMO Biosciences, Inc., 2265 East Foothill Boulevard, Pasadena, California 91107, United States

Department of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California 91010, United States

Department of Surgery and Moores Cancer Center, UC San Diego Health, 3855 Health Sciences Drive, La Jolla, California 92037, United States

Funding

National Cancer Institute

References (29)

Show source-provided references
1. 10.1016/j.tibs.2009.01.00410.1016/j.tibs.2009.01.004 ↗
2. 10.1074/jbc.R80005020010.1074/jbc.R800050200 ↗
3. 10.1016/j.molcel.2005.03.01210.1016/j.molcel.2005.03.012 ↗
4. 10.1038/ni.334210.1038/ni.3342 ↗
5. 10.1073/pnas.180211411510.1073/pnas.1802114115 ↗
6. 10.1084/jem.2010115910.1084/jem.20101159 ↗
7. 10.1084/jem.2010115810.1084/jem.20101158 ↗
8. 10.1038/nchembio.246310.1038/nchembio.2463 ↗
9. 10.1038/290475a010.1038/290475a0 ↗
10. 10.1016/j.cell.2012.03.00310.1016/j.cell.2012.03.003 ↗
11. 10.1016/j.semcancer.2006.07.01510.1016/j.semcancer.2006.07.015 ↗
12. 10.1016/j.cell.2009.05.00610.1016/j.cell.2009.05.006 ↗
13. 10.1126/science.121272810.1126/science.1212728 ↗
14. 10.1093/nar/gky48410.1093/nar/gky484 ↗
15. 10.1038/ncomms1232610.1038/ncomms12326 ↗
16. 10.1016/j.chembiol.2018.10.02610.1016/j.chembiol.2018.10.026 ↗
17. 10.1038/s41467-018-07015-110.1038/s41467-018-07015-1 ↗
18. 10.1038/sj.emboj.760055210.1038/sj.emboj.7600552 ↗
19. 10.1038/nature0876510.1038/nature08765 ↗
20. 10.1002/anie.20150580010.1002/anie.201505800 ↗
21. 10.1021/acs.jctc.5b0043610.1021/acs.jctc.5b00436 ↗
22. 10.1002/wcms.152110.1002/wcms.1521 ↗
23. 10.1021/acs.jctc.0c0039510.1021/acs.jctc.0c00395 ↗
24. 10.1063/5.002139910.1063/5.0021399 ↗
25. 10.1021/acs.jctc.1c0097410.1021/acs.jctc.1c00974 ↗
26. 10.1038/s41467-018-07015-110.1038/s41467-018-07015-1 ↗
27. 10.1093/nar/gky42710.1093/nar/gky427 ↗
28. DeLano W. L. · CCP4 Newsletter of Protein Crystallography · 2002 · 40 · 82
29. 10.1038/nature0876510.1038/nature08765 ↗